Achieve Life Sciences Q2 loss widens on warrant liabilities
ACHV•Outlook
- Achieve expects to resubmit cytisinicline NDA in Q4 2026, naming Adare as manufacturer
- Company anticipates potential FDA approval in first half of 2027, with U.S. commercial launch to follow
- Proceeds from $354 mln private placement expected to fund ORCA-V2 trial and commercialization
Overview
- US specialty pharma firm's Q2 net loss and loss per share missed analyst expectations
- Q2 net loss includes $48.7 mln non-cash charge from warrant liabilities
- Company closed private placement of up to $354 mln to fund cytisinicline program
Key details
| Metric | Beat/Miss | Actual | Consensus Estimate |
|---|---|---|---|
| Q2 Loss Per Share | Miss | $0.80 | $0.16 (10 Analysts) |
| Q2 Net Loss | Miss | $74.77 mln | $13.25 mln (9 Analysts) |
| Q2 Income From Operations | Miss | -$18.39 mln | -$13.50 mln (8 Analysts) |
| Q2 Operating Expenses | $18.39 mln |
Analyst coverage
- The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
